Literature DB >> 1730878

Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages.

L G Frigeri1, F T Liu.   

Abstract

IgE-binding protein (epsilon BP) is a galactoside-specific lectin containing an S-type carbohydrate-recognition domain. It was originally identified in rat basophilic leukemia cells and is now known to be identical to a macrophage surface Ag, Mac-2, and lectins designated as CBP 35/L-34/RL-29. It has also been related to a nonintegrin laminin-binding protein isolated from mouse macrophages. In this report we have shown the following: epsilon BP is present in variable amounts in several mast cell lines, and the surface expression of epsilon BP in these cell lines is quite variable and does not correlate with the total amount of epsilon BP in the cell. epsilon BP is displayed on the cell surface in a manner that is reversible by lactose, most likely through attachment to yet unidentified glycoconjugates. The putative epsilon BP binding sites on the cell surface can be readily demonstrated by using radiolabeled epsilon BP, and the sites are present in comparable amounts in various cell lines. Expression of epsilon BP on the cell surface can be regulated; the most notable example is the upregulation of surface epsilon BP on RBL cells activated through the high-affinity IgE receptor by IgE immune complexes. Cell-surface epsilon BP is functional as measured by its ability to promote adhesion of trypsinized rabbit erythrocytes to mast cells and macrophages. On the basis of these results and reported properties of related lectins, we propose that the lectin represented by epsilon BP is a new class of cell-adhesion protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730878

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 2.  Galectins in parasite infection and allergic inflammation.

Authors:  Anna R Young; Els N Meeusen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 3.  Seeing strangers or announcing "danger": galectin-3 in two models of innate immunity.

Authors:  Sachiko Sato; Julie Nieminen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 4.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

5.  Expression of galectin-3 modulates T-cell growth and apoptosis.

Authors:  R Y Yang; D K Hsu; F T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 6.  Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity.

Authors:  Juan P Cerliani; Sean R Stowell; Iván D Mascanfroni; Connie M Arthur; Richard D Cummings; Gabriel A Rabinovich
Journal:  J Clin Immunol       Date:  2010-12-24       Impact factor: 8.317

7.  Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses.

Authors:  D K Hsu; R Y Yang; Z Pan; L Yu; D R Salomon; W P Fung-Leung; F T Liu
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

8.  Galectin-3 expression in human atherosclerotic lesions.

Authors:  M Nachtigal; Z Al-Assaad; E P Mayer; K Kim; M Monsigny
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 9.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

10.  Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice.

Authors:  Maurice Nachtigal; Abdul Ghaffar; Eugene P Mayer
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.